Kowa Company, Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘Kowa Company, Ltd. – Product Pipeline Review – 2016’, provides an overview of the Kowa Company, Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kowa Company, Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kowa Company, Ltd.

The report provides overview of Kowa Company, Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Kowa Company, Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Kowa Company, Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kowa Company, Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kowa Company, Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kowa Company, Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Kowa Company, Ltd. Snapshot 6

Kowa Company, Ltd. Overview 6

Key Information 6

Key Facts 6

Kowa Company, Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

Kowa Company, Ltd. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Kowa Company, Ltd. - Pipeline Products Glance 14

Kowa Company, Ltd. - Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Kowa Company, Ltd. - Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Kowa Company, Ltd. - Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Discovery Products/Combination Treatment Modalities 19

Kowa Company, Ltd. - Unknown Stage Pipeline Products 20

Unknown Products/Combination Treatment Modalities 20

Kowa Company, Ltd. - Drug Profiles 21

pemafibrate 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

anagliptin 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

peretinoin 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

K-134 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ripasudil 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

epirubicin hydrochloride 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

K-312 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

pitavastatin NP 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecule to Agonize LXRB for Atherosclerosis 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule for Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

K-163SZ 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Kowa Company, Ltd. - Pipeline Analysis 38

Kowa Company, Ltd. - Pipeline Products by Target 38

Kowa Company, Ltd. - Pipeline Products by Route of Administration 40

Kowa Company, Ltd. - Pipeline Products by Molecule Type 41

Kowa Company, Ltd. - Pipeline Products by Mechanism of Action 42

Kowa Company, Ltd. - Recent Pipeline Updates 44

Kowa Company, Ltd. - Dormant Projects 47

Kowa Company, Ltd. - Discontinued Pipeline Products 48

Discontinued Pipeline Product Profiles 48

pitavastatin CR 48

Kowa Company, Ltd. - Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Kowa Company, Ltd., Key Information 6

Kowa Company, Ltd., Key Facts 6

Kowa Company, Ltd. – Pipeline by Indication, 2016 9

Kowa Company, Ltd. – Pipeline by Stage of Development, 2016 10

Kowa Company, Ltd. – Monotherapy Products in Pipeline, 2016 11

Kowa Company, Ltd. – Partnered Products in Pipeline, 2016 12

Kowa Company, Ltd. – Partnered Products/ Combination Treatment Modalities, 2016 13

Kowa Company, Ltd. – Pre-Registration, 2016 14

Kowa Company, Ltd. – Phase III, 2016 15

Kowa Company, Ltd. – Phase II, 2016 16

Kowa Company, Ltd. – Phase I, 2016 17

Kowa Company, Ltd. – Preclinical, 2016 18

Kowa Company, Ltd. – Discovery, 2016 19

Kowa Company, Ltd. – Unknown, 2016 20

Kowa Company, Ltd. – Pipeline by Target, 2016 39

Kowa Company, Ltd. – Pipeline by Route of Administration, 2016 40

Kowa Company, Ltd. – Pipeline by Molecule Type, 2016 41

Kowa Company, Ltd. – Pipeline Products by Mechanism of Action, 2016 43

Kowa Company, Ltd. – Recent Pipeline Updates, 2016 44

Kowa Company, Ltd. – Dormant Developmental Projects,2016 47

Kowa Company, Ltd. – Discontinued Pipeline Products, 2016 48

Kowa Company, Ltd., Other Locations 49

Kowa Company, Ltd., Subsidiaries 50

List of Figures

List of Figures

Kowa Company, Ltd. – Pipeline by Top 10 Indication, 2016 8

Kowa Company, Ltd. – Pipeline by Stage of Development, 2016 10

Kowa Company, Ltd. – Monotherapy Products in Pipeline, 2016 11

Kowa Company, Ltd. – Partnered Products in Pipeline, 2016 12

Kowa Company, Ltd. – Pipeline by Top 10 Target, 2016 38

Kowa Company, Ltd. – Pipeline by Route of Administration, 2016 40

Kowa Company, Ltd. – Pipeline by Molecule Type, 2016 41

Kowa Company, Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 42

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports